ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC.

Area of Science:

• Pharmacogenomics
• Molecular Oncology
• Cancer Biomarkers

Background:

• Non-small cell lung cancer (NSCLC) treatment efficacy varies.
• ATP-binding cassette (ABC) transporters influence drug response.
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) are key NSCLC therapies.

Purpose of the Study:

• To investigate the association between ABC transporter gene polymorphisms and EGFR-TKI sensitivity in NSCLC.
• To identify potential genetic biomarkers for predicting treatment efficacy.

Main Methods:

• Real-time PCR quantified ABC transporter mRNA expression in 16 NSCLC cell lines.
• IC50 values of gefitinib and osimertinib were correlated with mRNA expression.
• Single nucleotide polymorphisms (SNPs) in ABC transporter genes were analyzed in cell lines and patient blood samples.
• Clinical data from 109 first-generation and 54 third-generation EGFR-TKI treated patients were analyzed.

Main Results:

• No significant correlation between ABC transporter mRNA expression and EGFR-TKI sensitivity was observed in cell lines.
• Specific ABC transporter SNPs showed significant correlation with drug cytotoxicity in vitro.
• The ABCB1 C1236T T/T genotype was linked to longer progression-free survival (PFS) with first-generation EGFR-TKIs.
• The ABCC10 T2843C T/T genotype was associated with longer PFS in patients receiving third-generation EGFR-TKIs.

Conclusions:

• ABC transporter gene polymorphisms, specifically SNPs, show potential as predictive biomarkers for EGFR-TKI efficacy in NSCLC.
• These findings support the use of pharmacogenomics for personalized NSCLC treatment strategies.
• Further validation is needed to integrate these SNPs into clinical practice for improved patient outcomes.